Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Study Identifier:
D928FC00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Mar 2024 - Feb 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Mar 2024 - Feb 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Trial Locations

Location
Status
Location
Research Site
Alabaster, Alabama, United States, 35007
Status
Recruiting
Location
Research Site
Phoenix, Arizona, United States, 85054
Status
Not yet recruiting
Location
Research Site
Loma Linda, California, United States, 92354
Status
Not yet recruiting
Location
Research Site
Los Angeles, California, United States, 90022
Status
Recruiting
Location
Research Site
Los Angeles, California, United States, 90027
Status
Recruiting
Location
Research Site
Los Angeles, California, United States, 90095
Status
Recruiting